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risk prediction methods, estimate a predicted risk of dia-
betes and CHD. The economic evaluation thus captured
patient-relevant outcomes of MetS or diabetes/CHD
events avoided. METHODS: MetS was deﬁned according
to NCEP (ATPIII) guidelines, with modiﬁcations reﬂect-
ing clinically meaningful changes in risk factors. Lab 
measures were derived from a randomised double-blind,
head-to-head trial. The cumulative incidence of MetS was
computed using Kaplan-Meier analysis and compared
across treatment arms for 6 months of follow-up. The 5-
year diabetes and CHD risks were estimated from each
individual patient’s risk factor proﬁle for diabetes and
CHD using a published logistic regression and Weibull
model, respectively. Resource utilisation and costs were
derived from the underlying trial and published data.
Cost analysis was based on a Swedish third party payer
perspective. RESULTS: The results showed a 65% rela-
tive risk reduction (RRR) in MetS incidence at 6 months,
a 30% RRR in diabetes and 22% RRR in CHD incidence
at 5 years for Aripiprazole versus Olanzapine. For a hypo-
thetical cohort of 1000 patients switched from Olanzap-
ine to Aripiprazole, at study endpoint 124 events of MetS,
37 events of diabetes and 6 events of CHD are avoided,
showing cost savings due to reduced medical treatment
of side-effects of SEK 101.360 for MetS, 3.035.000 SEK
for Diabetes and 880.000 SEK for CHD. CONCLU-
SIONS: The results highlight a medical and economic
beneﬁt from maintenance therapy of Aripiprazole versus
Olanzapine, reﬂected by lower costs and a reduced inci-
dence of MetS, Diabetes and CHD.
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OBJECTIVE: Although schizophrenia is a common 
and disabling medical condition, little is known about 
its impact on health-related quality of life (HRQoL) in
Asians. We therefore characterized HRQoL in outpatients
with schizophrenia in Singapore, and identiﬁed factors
that inﬂuenced HRQoL in these patients. METHODS: A
consecutive sample of outpatients with schizophrenia
seen in the Institute of Mental Health in Singapore com-
pleted a standardized English or Chinese questionnaire
containing the Schizophrenia Quality of Life Scale
(SQLS), the Short Form 36 Health Survey (SF-36) and the
Health Utilities Index Mark 3 (HUI3) classiﬁcation
system. Patients were assessed for psychiatric symptoms
using a standard checklist, and socio-economic and clin-
ical variables were collected through patient interviews
and data extraction from medical records. Subjects’ SF-
36 scores were compared with adjusted Singaporean pop-
ulation norms. Factors inﬂuencing HRQoL measured by
these instruments were identiﬁed using stepwise multiple
linear regression models. RESULTS: Two hundred two
outpatients with schizophrenia completed survey ques-
tionnaires (English-speaking: n = 140). Mean (SD) age of
the subjects was 37.8 (10.2) years, and 52% were female.
The majority of the subjects were ethnic Chinese (83.7%).
The mean (SD) duration of schizophrenia was 8.4 (7.4)
years, and 30.7% of subjects reported hospitalization in
a psychiatric ward in the 3 months preceding the survey.
Mean SF-36 scores of the subjects were 4.7 to 37.2 points
lower than adjusted Singaporean population norms (p <
0.01 for all comparisons, one-sample t-tests). Better
HRQoL in these subjects (in stepwise regression models)
was associated with less psychiatric symptoms, increasing
age and duration of illness, less years of education, pres-
ence of chronic medical conditions and usage of English
questionnaires. CONCLUSIONS: Outpatients with schiz-
ophrenia in Singapore experienced clinically important
reductions in HRQoL; both disease related and other
variables inﬂuenced HRQoL in these patients.
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OBJECTIVES: In a 6-week randomized, double-blind
trial, olanzapine was associated with signiﬁcant increases
in triglycerides, low-density lipoprotein cholesterol
(LDL), and total cholesterol (TC), while ziprasidone 
was not. We compared changes in risk of coronary heart
disease (CHD) in olanzapine- and ziprasidone-treated
patients in this trial. METHODS: We analyzed data from
trial participants aged ≥30 years using a Framingham
data-based algorithm (Circulation 1998; 97: 1837–1847)
that calculates percentage risk of CHD over 10 years from
age, gender, smoking status, presence of diabetes, high-
density lipoprotein cholesterol (HDL), LDL or TC, and
diastolic and systolic blood pressures. Changes from base-
line to endpoint in percentage age-adjusted risk of CHD
for men and women in ziprasidone and olanzapine treat-
ment groups were compared using ANCOVA. RESULTS:
Mean age was approximately 42 years for both the
ziprasidone (range 30 to 55) and olanzapine (range 30 to
59) groups. In olanzapine-treated men (n = 55), risk of
CHD increased by 0.8% from a baseline of 4.2% while
in ziprasidone-treated men (n = 44) risk decreased by
0.2% from a baseline of 4.5% (p < 0.05). Olanzapine-
treated females (n = 18) had a 0.2% decrease in risk (base-
line, 3%) while ziprasidone-treated females (n = 21) had
a 0.4% increase (baseline, 2.5%) (p = NS). Analysis of
treatment-associated changes in lipids in patients of all
ages by gender found signiﬁcant changes in TC, LDL, and
triglycerides in olanzapine-treated men of all ages (n = 82)
versus ziprasidone-treated men (n = 69) (p < 0.005), with
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changes in triglycerides in olanzapine-treated women 
(n = 32) versus ziprasidone-treated women (n = 44) trend-
ing toward signiﬁcance (p = 0.09). CONCLUSIONS: In
a six-week trial, men treated with olanzapine experienced
an increase in CHD risk that was signiﬁcant versus a
decrease in men treated with ziprasidone, while changes
in risk did not differ signiﬁcantly between olanzapine-
and ziprasidone-treated women. These results paralleled
changes in lipid proﬁle. Investigation is warranted into
effects of long-term treatment with atypical antipsy-
chotics on risk of CHD.
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OBJECTIVES: Since end-users of survey may have design
format preferences that are undetected by survey devel-
oper/administrators, we elicited client and staff input and
preferences for three survey formats of a 51-item health-
related quality of life survey for community-residing indi-
viduals with schizophrenia. METHODS: Using cognitive
interviews and visual analogue preference ratings (0–100
scale), we sought qualitative and quantitative input from
29 community-residing clients with schizophrenia and 33
staff members at four sites concerning their preferences
for three formats of the 51-item Schizophrenia Outcomes
Assessment Project (SOAP-51) Survey: a 6-page booklet
with responses horizontally listed below each item, a 
4-page version with responses to the right of each item,
and a compressed 2-page version of the former. Survey
formats were presented in randomized order. Staff was
also asked their preference for four versus ﬁve-response
format. Clients were individually interviewed in 15–20
minutes sessions; staff had individual (20–30 minutes) or
group (45–60 minute) sessions. RESULTS: Clients pre-
ferred the booklet and 4-page format over the 2-page
version; respective VAS values of 70.1, 68.9, and 47.0 
(p = 0.012). Qualitatively, clients indicated that the 2-
page was too compressed and that the 4-page format
made it easier to link the response to the question. Staff
preferred 4 responses to 5 (84.0 versus 46.1, p < 0.0001)
because they perceived little distinction between two of
the ﬁve response levels. Staff had a preference trend
toward the 4-page format over the booklet or 2-page
(68.6, 58.6, and 58.9 respectively, p = 0.22). When asked
their ﬁrst choice, 47% of staff indicated 4-page; 34%, 2-
page; and 19%, booklet. CONCLUSIONS: Clients pre-
ferred booklet and 4-page formats; staff preferred 4-page
and 2-page formats. Based on this input, we have selected
the 4-page format, the common preference of both
groups. Survey developers should incorporate end-users
to provide insight into format preferences and cognitive
processing.
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OBJECTIVES: To study the long-term impact of psy-
chostimulant treatment on substance abuse and school
outcomes in a population-based cohort of AD/HD cases.
METHODS: Subjects included 282 AD/HD research
identiﬁed cases treated with psychostimulant medication
and 81 AD/HD cases that were never treated with 
psychostimulants. These subjects are subsets of the 363
research identiﬁed cases from a population-based birth
cohort, born in Rochester, MN 1976–1992 who
remained in Rochester after age 5 (N = 5,718). All 363
cases were followed from age 5 until emigration, death,
school graduation, drop out. Among 282 treated with
stimulants, 85% (N = 239) of cases were treated with
methylphenidate. Data on type of psychostimulant,
dosage prescribed (Methylphenidate Equivalent Units),
start/stop dates were collected from medical and school
records. The same resources were retrospectively and lon-
gitudinally examined for the documentation of substance
abuse and school outcomes. Associations between 
psychostimulant treatment and outcomes were evaluated
using general linear and logistic regression models.
RESULTS: Of the AD/HD cases treated with stimulants,
16.3% had documented substance abuse compared to
23.5% cases not treated (OR = 0.6; 95% CI = 0.3–1.2;
p = 0.14). Cases treated at an earlier age were less likely
to have documented substance abuse (p = 0.025) as well
as those treated for a longer duration (p = 0.17). Cases
with higher average daily psychostimulant dosage had
higher reading scores (r = 0.14, p = 0.025). Cases treated
with psychostimulants were absent signiﬁcantly less than
those who were not treated (p = 0.024). Furthermore,
cases treated longer were absent less (r = -0.18, p =
0.003). CONCLUSIONS: Our large, longitudinal, popu-
lation-based, study demonstrates that psychostimulant
treatment is associated with decreased substance abuse
and improved school outcomes among AD/HD cases.
Our study conﬁrms the positive impact and importance
of long-term treatment with psychostimulants and reﬂects
an improvement in the lives of children with AD/HD.
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